452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620644
Title:
452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration.
Authors:
Lamarca, Angela; Barriuso, Jorge; McCallum, Lynne; Papaxoinis, Georgios; Nasralla, Magdy; Nuttall, Christina; Frizziero, Melissa; Kordatou, Zoe; McNamara, Mairéad G ( 0000-0002-2272-3678 ) ; Hubner, Richard A ( 0000-0002-7081-8823 ) ; Manoharan, Prakash; Mansoor, Was; Valle, Juan W ( 0000-0002-1999-0863 )
Affiliation:
Medical Oncology, The Christie NHS Foundation Trust, Manchester
Citation:
452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration. 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620644
DOI:
10.1093/annonc/mdx368.024
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368.024/4108673/452PTemozolomidecapecitabine-TemCap-chemotherapy
Type:
Meetings and Proceedings
Language:
en_US
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLamarca, Angelaen
dc.contributor.authorBarriuso, Jorgeen
dc.contributor.authorMcCallum, Lynneen
dc.contributor.authorPapaxoinis, Georgiosen
dc.contributor.authorNasralla, Magdyen
dc.contributor.authorNuttall, Christinaen
dc.contributor.authorFrizziero, Melissaen
dc.contributor.authorKordatou, Zoeen
dc.contributor.authorMcNamara, Mairéad Gen
dc.contributor.authorHubner, Richard Aen
dc.contributor.authorManoharan, Prakashen
dc.contributor.authorMansoor, Wasen
dc.contributor.authorValle, Juan Wen
dc.date.accessioned2017-11-21T21:42:36Z-
dc.date.available2017-11-21T21:42:36Z-
dc.date.issued2017-09-
dc.identifier.citation452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx368.024-
dc.identifier.urihttp://hdl.handle.net/10541/620644-
dc.language.isoen_USen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368.024/4108673/452PTemozolomidecapecitabine-TemCap-chemotherapyen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title452P Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): time to maximum response and optimal treatment duration.en_US
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.